Lineage Cell Therapeutics, INC Schedule 13D activist filings
Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.
AMEX
Broadwood Partners and affiliates reported a decrease in their beneficial ownership of Lineage Cell Therapeutics common shares to 23.1% following the issuer's recent share sale.
AMEX
SCHEDULE 13D/A: Broadwood Entities Increase Stake in Lineage Cell Therapeutics to 24.5% Following Shareholder Approval
Broadwood Partners, Broadwood Capital, and Neal C. Bradsher have increased their beneficial ownership in Lineage Cell Therapeutics, Inc. to 24.5% following a shareholder vote approving a significant transaction.